Sigma Planning Corp Sells 13,910 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Sigma Planning Corp decreased its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 54.0% in the fourth quarter, Holdings Channel reports. The firm owned 11,870 shares of the biotechnology company’s stock after selling 13,910 shares during the period. Sigma Planning Corp’s holdings in Rocket Pharmaceuticals were worth $356,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Rocket Pharmaceuticals by 96.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,068 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 1,014 shares in the last quarter. Annandale Capital LLC acquired a new stake in shares of Rocket Pharmaceuticals in the 3rd quarter worth $66,000. Allspring Global Investments Holdings LLC boosted its position in shares of Rocket Pharmaceuticals by 14.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,145 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 633 shares in the last quarter. Harbour Capital Advisors LLC acquired a new stake in shares of Rocket Pharmaceuticals in the 4th quarter worth $282,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Rocket Pharmaceuticals by 7.9% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,477 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 981 shares in the last quarter. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Stock Performance

NASDAQ RCKT opened at $21.98 on Friday. The stock has a 50-day simple moving average of $26.70 and a two-hundred day simple moving average of $25.41. The firm has a market capitalization of $1.99 billion, a P/E ratio of -7.48 and a beta of 1.07. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $14.89 and a fifty-two week high of $32.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.80 and a current ratio of 7.80.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.14. During the same period in the previous year, the business posted ($0.92) EPS. On average, equities analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.94 earnings per share for the current year.

Insider Activity at Rocket Pharmaceuticals

In related news, insider Kinnari Patel sold 7,132 shares of Rocket Pharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $29.84, for a total value of $212,818.88. Following the completion of the transaction, the insider now owns 238,346 shares in the company, valued at approximately $7,112,244.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Kinnari Patel sold 7,132 shares of Rocket Pharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $29.84, for a total value of $212,818.88. Following the completion of the transaction, the insider now owns 238,346 shares in the company, valued at approximately $7,112,244.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John Militello sold 2,490 shares of Rocket Pharmaceuticals stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $28.10, for a total value of $69,969.00. Following the completion of the transaction, the insider now owns 55,239 shares of the company’s stock, valued at approximately $1,552,215.90. The disclosure for this sale can be found here. Insiders sold a total of 414,935 shares of company stock worth $11,476,424 in the last 90 days. Corporate insiders own 31.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their target price on Rocket Pharmaceuticals from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Tuesday, February 27th. StockNews.com upgraded Rocket Pharmaceuticals to a “sell” rating in a research note on Friday, February 9th. Needham & Company LLC restated a “buy” rating and issued a $53.00 target price on shares of Rocket Pharmaceuticals in a research note on Wednesday, April 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, February 27th. Finally, UBS Group reduced their target price on Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a research note on Friday, March 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.13.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.